Literature DB >> 29231774

Modern management of diabetic foot osteomyelitis. The when, how and why of conservative approaches.

Javier Aragón-Sánchez1, Benjamin A Lipsky2,3.   

Abstract

INTRODUCTION: Diabetic foot osteomyelitis (DFO) has long been considered a complex infection that is both difficult to diagnose and treat, and is associated with a high rate of relapse and limb loss. Areas covered: DFO can usually be diagnosed by a combination of clinical evaluation, serum inflammatory markers and plain X-ray. When the results of these procedures are negative or contradictory, advanced imaging tests or bone biopsy may be necessary. Staphylococcus aureus remains the most frequent microorganism isolated from bone specimens, but infection is often polymicrobial. Antibiotic therapy, preferably with oral agents guided by results of bone culture, for a duration of no more than six weeks, appears to be as safe and effective as surgery in cases of uncomplicated forefoot DFO. Surgery (which should be limb-sparing when possible) is always required for DFO accompanied by necrotizing fasciitis, deep abscess, gangrene or in cases not responding (either clinically or radiographically) to apparently appropriate antibiotic treatment. Expert commentary: Research in the past decade has improved diagnosis and treatment of DFO, and most cases can now be managed with a 'conservative' approach, defined as treatment either exclusively with antibiotics or with surgery removing as little bone and soft tissue as necessary.

Entities:  

Keywords:  Bone infections; conservative surgery; diabetic foot osteomyelitis; foot ulcers; wound infection

Mesh:

Substances:

Year:  2017        PMID: 29231774     DOI: 10.1080/14787210.2018.1417037

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  8 in total

1.  The role of reconstructive microsurgery in treating lower-extremity chronic wounds.

Authors:  Hyunsuk Peter Suh; Joon Pio Hong
Journal:  Int Wound J       Date:  2019-05-30       Impact factor: 3.315

2.  Citrobacter koseri causing osteomyelitis in a diabetic foot with concomitant acute gouty arthritis successfully treated with ertapenem.

Authors:  Dillon Tinevez; Nebojsa Nick Knezevic
Journal:  BMJ Case Rep       Date:  2019-07-27

3.  Foot Osteomyelitis Location and Rates of Primary or Secondary Major Amputations in Patients With Diabetes.

Authors:  Elin Winkler; Madlaina Schöni; Nicola Krähenbühl; Ilker Uçkay; Felix W A Waibel
Journal:  Foot Ankle Int       Date:  2022-05-18       Impact factor: 3.569

Review 4.  Optimal management of diabetic foot osteomyelitis: challenges and solutions.

Authors:  José Luis Lázaro Martínez; Yolanda García Álvarez; Aroa Tardáguila-García; Esther García Morales
Journal:  Diabetes Metab Syndr Obes       Date:  2019-06-21       Impact factor: 3.168

5.  Microbiological Concordance in the Management of Diabetic Foot Ulcer Infections with Osteomyelitis, on the Basis of Cultures of Different Specimens at a Diabetic Foot Center in China.

Authors:  Xuemei Li; Qingfeng Cheng; Zhipeng Du; Shenyin Zhu; Chao Cheng
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-06       Impact factor: 3.168

6.  Conservative surgery for chronic diabetic foot osteomyelitis: Procedures and recommendations.

Authors:  José Luis Lázaro-Martínez; Marta García-Madrid; Yolanda García-Álvarez; Francisco Javier Álvaro-Afonso; Irene Sanz-Corbalán; Esther García-Morales
Journal:  J Clin Orthop Trauma       Date:  2020-12-15

Review 7.  The Influence of Multidrug-Resistant Bacteria on Clinical Outcomes of Diabetic Foot Ulcers: A Systematic Review.

Authors:  Gianmarco Matta-Gutiérrez; Esther García-Morales; Yolanda García-Álvarez; Francisco Javier Álvaro-Afonso; Raúl Juan Molines-Barroso; José Luis Lázaro-Martínez
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

Review 8.  Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives.

Authors:  Fatemah Sadeghpour Heravi; Martha Zakrzewski; Karen Vickery; David G Armstrong; Honghua Hu
Journal:  J Clin Med       Date:  2019-11-10       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.